Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $205 to $201.
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $205 to $201.